Result of Retail Offer and Total Voting Rights

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to confirm, further to the announcements made on 4 December 2024, the result of its significantly oversubscribed Retail Offer and Capital Raise at the Issue Price of 10.5 pence per share. The Company announces that it has, conditional on Admission, raised aggregate gross proceeds of approximately £1 million pursuant to the Retail Offer. This is in addition to the previously announced oversubscribed Placing and Subscription which had significant participation from both existing and new healthcare specialist investors. Accordingly, the Company will issue a total of 9,523,809 new Ordinary Shares at the Issue Price pursuant to the Retail Offer.

In total, the Placing, Subscription and the Retail Offer have raised gross proceeds of approximately £11.3 million in aggregate for the Company.

Admission and Total Voting Rights

Application has been made for the Placing Shares, the Subscription Shares and the Retail Offer Shares to be admitted to trading on AIM ("Admission"). Admission is expected to become effective on or around 10 December 2024.

Upon Admission, the Company's issued ordinary share capital will consist of 1,036,781,403 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission the total number of Ordinary Shares and voting rights in the Company will be 1,036,781,403. With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 5:59 pm on 4 December 2024.

Scancell Holdings plc +44 (0) 20 3709 5700 Phil L'Huillier, CEO Professor Lindy Durrant, CSO Dr Jean-Michel Cosséry, Non-Executive Chairman Panmure Liberum Limited (Joint Bookrunner, Joint Broker and Nominated Advisor) +44 (0) 20 7886 2500 Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) WG Partners LLP (Joint Bookrunner and Joint Broker) David Wilson, Claes Spang, Satheesh Nadarajah, Erland Sternby +44 (0) 20 3705 9330 ICR Healthcare Mary-Jane Elliott, Angela Gray, Lindsey Neville +44 (0) 20 3709 5700 scancell@icrhealthcare.com Winterflood Retail Access Platform WRAP@winterflood.com Joe Winkley, Sophia Bechev 0203 100 0286

Further information on the Company can be found on its website at www.scancell.co.uk.

The Company's LEI is 2138008RXEG856SNP666.